Checchi Capital Advisers LLC Invests $219,000 in Axon Enterprise, Inc $AXON

Checchi Capital Advisers LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 264 shares of the biotechnology company’s stock, valued at approximately $219,000.

A number of other institutional investors also recently modified their holdings of the company. Willner & Heller LLC bought a new position in Axon Enterprise in the second quarter worth about $215,000. 111 Capital bought a new position in Axon Enterprise in the second quarter worth about $267,000. QRG Capital Management Inc. raised its stake in Axon Enterprise by 4.6% in the second quarter. QRG Capital Management Inc. now owns 1,303 shares of the biotechnology company’s stock worth $1,079,000 after buying an additional 57 shares in the last quarter. Segment Wealth Management LLC raised its stake in Axon Enterprise by 11.0% in the second quarter. Segment Wealth Management LLC now owns 4,070 shares of the biotechnology company’s stock worth $3,370,000 after buying an additional 404 shares in the last quarter. Finally, Fortis Capital Advisors LLC bought a new position in Axon Enterprise in the second quarter worth about $220,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, President Joshua Isner sold 15,919 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the sale, the president owned 238,379 shares in the company, valued at $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeri Williams sold 100 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director owned 1,416 shares in the company, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 49,932 shares of company stock valued at $37,978,216. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ AXON opened at $714.60 on Wednesday. Axon Enterprise, Inc has a fifty-two week low of $420.49 and a fifty-two week high of $885.91. The company has a 50 day simple moving average of $757.21 and a two-hundred day simple moving average of $710.53. The company has a market capitalization of $56.10 billion, a price-to-earnings ratio of 176.44, a P/E/G ratio of 28.02 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter last year, the firm earned $1.20 earnings per share. The business’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on AXON. JMP Securities reissued a “market outperform” rating and issued a $825.00 price target on shares of Axon Enterprise in a research note on Monday, September 29th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an “overweight” rating in a research note on Friday, July 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Axon Enterprise in a research note on Saturday, September 27th. Finally, UBS Group reaffirmed a “neutral” rating and set a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.